These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 9235189)
1. [Post-treatment PSA, indicator of radical treatment effectiveness of localized cancer of the prostate]. Ravery V; Hermieu JF; Hoffmann P; Delmas V; Boccon-Gibod L Prog Urol; 1996 Dec; 6(6):981-6. PubMed ID: 9235189 [TBL] [Abstract][Full Text] [Related]
2. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
3. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912 [TBL] [Abstract][Full Text] [Related]
4. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793 [TBL] [Abstract][Full Text] [Related]
5. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Ravery V Semin Urol Oncol; 1999 Aug; 17(3):127-9. PubMed ID: 10462314 [TBL] [Abstract][Full Text] [Related]
6. [PSA and follow-up after treatment of prostate cancer]. Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065 [TBL] [Abstract][Full Text] [Related]
7. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Do T; Parker RG; Do C; Tran L; Do L; Dolkar D Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941 [TBL] [Abstract][Full Text] [Related]
9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328 [TBL] [Abstract][Full Text] [Related]
10. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of circulating prostate cells in patients with a rising PSA after radical prostatectomy. Tombal B; Van Cangh PJ; Loric S; Gala JL Prostate; 2003 Aug; 56(3):163-70. PubMed ID: 12772185 [TBL] [Abstract][Full Text] [Related]
12. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735 [TBL] [Abstract][Full Text] [Related]
14. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors]. Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198 [TBL] [Abstract][Full Text] [Related]
16. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840 [TBL] [Abstract][Full Text] [Related]
17. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412 [TBL] [Abstract][Full Text] [Related]
18. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2000 Apr; 163(4):1183-8. PubMed ID: 10737491 [TBL] [Abstract][Full Text] [Related]
19. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. Shen S; Lepor H; Yaffee R; Taneja SS J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268 [TBL] [Abstract][Full Text] [Related]
20. The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy. Taylor JA; Koff SG; Dauser DA; McLeod DG BJU Int; 2006 Sep; 98(3):540-3. PubMed ID: 16925750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]